Intra-Cellular Therapies reported its drug Caplyta met the main and secondary goals in the first of three pivotal studies in major depressive disorder. Success in two of them could support expanding the label of the drug, which is currently approved in schizophrenia and bipolar depression.
Seaport Therapeutics’ drug candidates are delivered through the lymphatic system, an approach that could overcome some limitations of neuropsychiatric medicines, including products from Sage Therapeutics. The startup stems from the research of PureTech Health.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Alto Neuroscience will apply the IPO proceeds toward clinical tests of its psychiatric drugs in patients who exhibit certain biomarkers. The company's two most advanced programs are depression drugs in mid-stage development.
An AI-driven app called juli improved symptoms of asthma and depression, two randomized controlled trials found. The app takes in data from electronic medical records, smartphones, wearable devices, the environment and patient questionnaires to provide personalized health recommendations.
Just 10% of women who had post-miscarriage depression during the pandemic received the “full spectrum of treatment” through therapy and antidepressants, according to a new report by Evernorth Research Institute.
Less than 20% of behavioral healthcare providers collect data on how patients are progressing with their treatment. To buck this trend, Two Chairs is rolling out “mental health snapshots,” which are consistent summaries of patients’ well-being designed to offer real-time insight to both clinicians and clients.
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
Lusaris Therapeutics launched with $60 million for clinical development of a psychedelic depression drug it claims will be easier to dose and fast-acting. The company was formed and incubated by RA Capital Management, which led the startup’s Series A round of financing.
A Relmada Therapeutics drug candidate for major depressive disorder failed a Phase 3 clinical trial, but the biotech isn’t giving up on its pill yet. It’s pinning its hopes on additional studies testing the therapy as an additional treatment alongside other depression drugs.
In order to make an impact and improve physical and mental health, we need to recognize the need to approach loneliness as a condition. Building connections through social intervention is the most direct way to affect change.
The FDA has approved Axsome Therapeutics drug Auvelity as a treatment for major depressive disorder in adults. The regulatory decision makes the twice-daily pill the first new oral drug approved to address a novel depression target in more than 60 years.
We will highlight Build My Health's revenue practice management tools, which could help physician practices add up to $250,000 to their practices.
Clinicians used to wonder if there was a role for mindfulness meditation in healthcare. But after the Covid-19 pandemic laid bare the overwhelming need for practical solutions in behavioral health, the question has shifted to what role it can play.
Eleusis is developing a formulation of the psychedelic compound psilocybin that overcomes limitations of pill versions of the drug. Depression is Eleusis’s lead disease target but the biotech notes that its research has shown the potential to bring psychedelic drugs beyond psychiatry.
Centers for Medicare & Medicaid Services only recently gave the green light for Medicare Advantage (MA) plans to provide a wider range of benefits that address social determinants of health. With that new charge, it’s time for health care payers to join the fight against loneliness.
A study published by Verily researchers showed that some smartphone metrics, such as sentiment in weekly voice diaries, matched up with the severity of users’ depression as determined by PHQ-9 scores. Even if these technologies could be used to track mental health, it’s not clear how they will fit into physician workflows or how comfortable people will be using their smartphones in this way.
The company recently finished a study showing patients in the U.K. who used both Sleepio’s app and therapy saw improvements in anxiety and depression compared to people who used therapy alone. But the study also had several limitations.